We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

1 hedge funds and large institutions have $0 invested in Cascadian Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 91 → 1 (-90)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $152M → $0 (-$152M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 90

Holders
1
Holders Change
-90
Holders Change %
-98.9%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
90
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$33.5M
2
BG
Baupost Group
Massachusetts
-$32.3M
3
BI
BVF Inc
California
-$11.6M
4
BlackRock
BlackRock
New York
-$10.1M
5
ACA
Avoro Capital Advisors
New York
-$9.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
– -$493K -133,328 Closed
Millennium Management
27
Millennium Management
New York
– -$419K -113,300 Closed
DCM
28
DAFNA Capital Management
California
– -$395K -106,810 Closed
UC
29
Unterberg Capital
New York
– -$370K -100,000 Closed
TCIM
30
TIAA CREF Investment Management
New York
– -$334K -90,243 Closed
Morgan Stanley
31
Morgan Stanley
New York
– -$330K -89,075 Closed
Handelsbanken Fonder
32
Handelsbanken Fonder
Sweden
– -$311K -84,000 Closed
Renaissance Technologies
33
Renaissance Technologies
New York
– -$302K -81,688 Closed
Deutsche Bank
34
Deutsche Bank
Germany
– -$299K -81,083 Closed
PCM
35
Prelude Capital Management
New York
– -$293K -79,155 Closed
Connor, Clark & Lunn Investment Management (CC&L)
36
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$270K -72,973 Closed
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
– -$238K -64,425 Closed
TA
38
Teachers Advisors
New York
– -$228K -61,621 Closed
Charles Schwab
39
Charles Schwab
California
– -$224K -60,500 Closed
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
– -$212K -57,192 Closed
AA
41
ALPS Advisors
Colorado
– -$207K -56,018 Closed
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
– -$205K -55,489 Closed
Bank of America
43
Bank of America
North Carolina
– -$184K -49,802 Closed
BTS
44
BB&T Securities
Virginia
– -$181K -48,999 Closed
Two Sigma Investments
45
Two Sigma Investments
New York
– -$181K -48,835 Closed
SG Americas Securities
46
SG Americas Securities
New York
– -$143K -38,541 Closed
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
– -$135K -36,500 Closed
PCM
48
Perkins Capital Management
Minnesota
– -$132K -35,632 Closed
ProShare Advisors
49
ProShare Advisors
Maryland
– -$120K -32,469 Closed
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
– -$118K -31,890 Closed
1
2
3 4

CASC Hedge Fund Activity: Q1 2018 in Review

1 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2018, worth a combined $0 — down 100% from $152M a quarter earlier.

Sellers outnumbered buyers: 90 funds closed out of CASC and 0 opened new positions — a net loss of 90 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was NEA Management Company, exiting entirely with an estimated $33.5M sold.

  • 1 institutional investor held Cascadian Therapeutics, Inc. (CASC) as of Q1 2018, down from 91 in Q4 2017.
  • Funds reported $0 of Cascadian Therapeutics, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2018 and 90 closed out, a net change of -90 holders.
  • The largest Cascadian Therapeutics, Inc. seller in Q1 2018 was NEA Management Company, an estimated $33.5M sold.

Based on aggregated 13F filings for Q1 2018.